The study and treatment
At the World Congress on Gastrointestinal Cancer, held in Barcelona, Spain, on July 3-6, 2019, updated results from a study of 663 metastatic colorectal cancer patients with a BRAF mutation were presented.
1 in 10 patients with metastatic colorectal cancer have a BRAF mutation in their tumor cells. This mutation is associated with a poor prognosis in these patients with a life expectancy of less than one year.
All patients in the study received one or two treatment lines for their metastatic disease. Patients were divided into 3 groups – in the first group, patients were treated with a triple combination of Mektovi + Cetuximab + Braftovi; in the second group, patients were treated with Erbitox + Braftovi. In the third group, patients were treated with the standard Eribitox with Irinotecan or Folfiri.
The patients treated with the triple combination lived almost twice as high as those treated with the standard only
Not only that, but their risk of mortality during treatment declined by half compared to those treated with the standard!
In addition, compared to the standard, the duration of their disease progression was three times higher than the standard and the risk of worsening of the disease during the treatment decreased by 62% …
And in terms of the rate of response – the percentage of patients who responded to the triple treatment, meaning that their disease was stopped or shrunk – it was almost 14 times higher than the standard !!
No less impressive results were observed in patients treated with combination of Erbitox and Braftovi vs standard and demonstrated life-prolongation; extension of time to disease progression; 10 times more patients who responded and decreased risk of mortality and disease progression.
In terms of side effects, all side effects were known from past experience in each of these treatments.
What does the future hold for patients with metastatic colorectal cancer with a BRAF mutation?
Now there is a study that examines the triple treatment as a first line treatment for metastatic disease and not in advanced lines. The study is open to recruitment in the United States, Austria, Belgium, France, Italy, the Netherlands, Spain and the UK.
It is worth asking your oncologist and not giving up – this innovative and advanced treatment can change your life!
There, the hope and the chance to extend life go far beyond the standard protocols.
Do not give up on life!
Contact us 24/7 for free service matching:
Call center +44.2082.426.039